Key Details
Price
$26.09Annual ROE
45.26%Beta
0.78Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
15 Nov '24 HC Wainwright & Co.
Buy11 Sept '24 Citigroup
Buy10 Sept '24 Oppenheimer
Outperform10 Sept '24 HC Wainwright & Co.
Buy10 Sept '24 Goldman Sachs
Buy16 Aug '24 HC Wainwright & Co.
Buy15 Aug '24 Oppenheimer
Outperform06 June '24 HC Wainwright & Co.
Buy09 May '24 HC Wainwright & Co.
Buy30 Apr '24 HC Wainwright & Co.
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
ArriVent BioPharma Common Stock doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
AVBP
marketbeat.com06 November 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
AVBP
globenewswire.com12 August 2024
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
AVBP
globenewswire.com16 May 2024
ArriVent BioPharma, Inc., a company focused on advancing innovative biopharmaceutical therapeutics globally, has appointed John Hohneker, M.D. to its Board of Directors. Dr. Hohneker, who has more than three decades of experience in biopharmaceutical leadership and drug development, currently sits on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., as well as private companies Sonata Therapeutics and Trishula Therapeutics.
ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
AVBP
Seeking Alpha29 January 2024
ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer.
FAQ
- What is the primary business of ArriVent BioPharma Common Stock?
- What is the ticker symbol for ArriVent BioPharma Common Stock?
- Does ArriVent BioPharma Common Stock pay dividends?
- What sector is ArriVent BioPharma Common Stock in?
- What industry is ArriVent BioPharma Common Stock in?
- What country is ArriVent BioPharma Common Stock based in?
- When did ArriVent BioPharma Common Stock go public?
- Is ArriVent BioPharma Common Stock in the S&P 500?
- Is ArriVent BioPharma Common Stock in the NASDAQ 100?
- Is ArriVent BioPharma Common Stock in the Dow Jones?
- When was ArriVent BioPharma Common Stock's last earnings report?
- When does ArriVent BioPharma Common Stock report earnings?
- Should I buy ArriVent BioPharma Common Stock stock now?
What is the primary business of ArriVent BioPharma Common Stock?
ArriVent BioPharma focuses on developing innovative therapies for patients with serious diseases. The company specializes in creating and advancing biopharmaceutical products, aiming to improve treatment options and outcomes in areas with high unmet medical needs. Their commitment is to enhance patient health through cutting-edge research and development.
What is the ticker symbol for ArriVent BioPharma Common Stock?
The ticker symbol for ArriVent BioPharma Common Stock is NASDAQ:AVBP
Does ArriVent BioPharma Common Stock pay dividends?
No, ArriVent BioPharma Common Stock does not pay dividends
What sector is ArriVent BioPharma Common Stock in?
ArriVent BioPharma Common Stock is in the Healthcare sector
What industry is ArriVent BioPharma Common Stock in?
ArriVent BioPharma Common Stock is in the Biotechnology industry
What country is ArriVent BioPharma Common Stock based in?
ArriVent BioPharma Common Stock is headquartered in United States
When did ArriVent BioPharma Common Stock go public?
ArriVent BioPharma Common Stock's initial public offering (IPO) was on 26 January 2024
Is ArriVent BioPharma Common Stock in the S&P 500?
No, ArriVent BioPharma Common Stock is not included in the S&P 500 index
Is ArriVent BioPharma Common Stock in the NASDAQ 100?
No, ArriVent BioPharma Common Stock is not included in the NASDAQ 100 index
Is ArriVent BioPharma Common Stock in the Dow Jones?
No, ArriVent BioPharma Common Stock is not included in the Dow Jones index
When was ArriVent BioPharma Common Stock's last earnings report?
ArriVent BioPharma Common Stock's most recent earnings report was on 14 November 2024
When does ArriVent BioPharma Common Stock report earnings?
The next expected earnings date for ArriVent BioPharma Common Stock is 28 February 2025
Should I buy ArriVent BioPharma Common Stock stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions